Page 30 - Risk Evaluation News Today

The FDA has approved extended-release injection buprenorphine (Brixadi, Braeburn Inc) for the treatment of moderate to severe opioid use disorder.

FPT Industrial, the Iveco Group brand dedicated to the design and manufacture of low-environmental-impact mobility solutions, and Edison Next, the Edison Group company which guides companies and... | May 22, 2023

'We are well poised to maintain growth momentum, with India geography likely to hold double-digit growth,' says Sharvil Patel, Managing Director, Zydus Lifesciences

For those now grappling with Alzheimer’s, lecanemab holds out the promise of slowing the disease’s progress. Are the modest benefits worth the risks? (C1)

The core premise of Bexis’ article is very simple: Once the FDA has said “yes” and approved a particular drug for a particular indication (“intended…

Judge pushes back on 'FDA-can-do-no-wrong' narrative

Session at the 2023 American Psychiatric Association Annual Meeting shares insights on REMS for psychiatric medications.

– Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Hematologic, Genitourinary, Gastrointestinal, Gynecological and... | May 17, 2023

If Administrator decides not to rely on other statutory authorities to address risks identified by TSCA risk evaluation, section 9b requires the Administrator to consider all relevant aspects of the risk and a comparison of the estimated costs and efficiencies of the action

Eight presentations at ASCO and EHA 2023 Annual Meetings showcase continued leadership in CAR-T cell therapy research for patients with multiple myeloma across various clinical settings First... | May 16, 2023